Principal Investigator
Shirin Shafazand
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20170905
Clinical Trial Summary
An open-label extension trial to assess the long term safety ofNintedanib in patients with €˜Systemic Sclerosis associatedInterstitial Lung Disease€™ (SSc-ILD)
Phase
Phase III
Funding Agency/Sponsor
Industry
Disease
Other
Contact Information
Study Contact
Emmanuelle Simonet
Phone Number
+1 (305) 2437298
Email
esimonet@miami.edu